FDA Approved: STRIVERDI RESPIMAT — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for STRIVERDI RESPIMAT (olodaterol) from Boehringer Ingelheim Pharmaceuticals, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Striverdi Respimat (olodaterol)

Snippet

SUPPL AP for STRIVERDI RESPIMAT (OLODATEROL RESPIMAT INHALATION SPRAY)